Hybio Pharmaceutical Co., Ltd.
Pharmaceutical industry · Shenzhen, Guangdong
About Hybio Pharmaceutical Co., Ltd.
Hybio Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company founded in 2003 and headquartered in Shenzhen, Guangdong Province, specialising in peptide drugs. Listed on Shenzhen's ChiNext market since 2011 (300199), it is presented on its official website as a national high-tech enterprise engaged in the research, production and sales of peptide medicines.
Its business is organised in four segments: peptide formulations — with products such as terlipressin, somatostatin, desmopressin and thymopentin, and international developments of semaglutide, liraglutide and glatiramer — peptide active ingredients and custom peptides, small nucleic acid drugs (oligonucleotides) and CRDMO services. Its main bases are in Shenzhen (Longhua and Pingshan) and Wuhan.
The official website publishes its headquarters at the Hybio Innovation Industry Park, No. 7 Guansheng 4th Road, Longhua District, together with its contact telephone. For buyers of peptide active ingredients and contract-development partners, Hybio is one of China's listed specialists with the broadest catalogue of chemically synthesised peptides.
Its business is organised in four segments: peptide formulations — with products such as terlipressin, somatostatin, desmopressin and thymopentin, and international developments of semaglutide, liraglutide and glatiramer — peptide active ingredients and custom peptides, small nucleic acid drugs (oligonucleotides) and CRDMO services. Its main bases are in Shenzhen (Longhua and Pingshan) and Wuhan.
The official website publishes its headquarters at the Hybio Innovation Industry Park, No. 7 Guansheng 4th Road, Longhua District, together with its contact telephone. For buyers of peptide active ingredients and contract-development partners, Hybio is one of China's listed specialists with the broadest catalogue of chemically synthesised peptides.